CURRENT POSSIBILITIES OF COMBINED THERAPY IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS
- Autores: Chemikova N.A1
-
Afiliações:
- FSBEIFPE «Russian Medical Academy of Continuous Postgraduate Education» of RMH
- Edição: Nº 5 (2017)
- Páginas: 86-90
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289813
- ID: 289813
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Combined therapy with inhibitors of sodium-glucose cotransporter 2nd type (SGLT-2) and metformin (additive effect on carbohydrate metabolism and complementary mechanism of action) provides a simultaneous effect on the multifactorial links of the pathogenesis of type 2 diabetes mellitus (DM2): safely reduces glycemia, reduces body weight and blood pressure that gives a high potential to this type of therapy. Sodium-glucose cotransporter type 2 inhibitors certainly play a positive role in the complex of therapeutic measures for the majority of DM2 patients and make this class of drugs a priority in modern appointments of diabetes specialists.
Texto integral
Sobre autores
N. Chemikova
FSBEIFPE «Russian Medical Academy of Continuous Postgraduate Education» of RMH
Email: nachendoc@yandex.ru
PhD, Associate Professor at the Department of Endocrinology Moscow
Bibliografia
- IDF Diabetes Atlas 7th Edition 2015 Update.
- Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405-12.
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
- Segel S.A., Paramore D.S., Cryer P.E. Hypo glycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002;51:724-33.
- Дедов И.И., Шестакова М.В. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 8-й выпуск. 2017.
- Rosenstock J., et al. WCIRDC. 2016. Poster 99. Уточнить ссылку (добавить авторов и название)
- Bolinder J., Ljunggren Ö., Kullberg J., Johansson L., Wilding J., Langkilde A.M., Sugg J., Parikh S. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J. Clin. Endocrinol. Metab. 2012; 97:1020-31.
- Аметов А.С., Парнес Е.Я., Черникова Н.А., Ермакова Е.А. Сахарный диабет 2 типа: проблемы и решения. Глава 6. Особенности патогенеза и течения артериальной гипертензии у пациентов с сахарным диабетом 2 типа. Связь между артериальной гипертонией и развитием осложнений. 3-е изд., переработ. и доп. М., 2016.
Arquivos suplementares
